The VP Engineering of Eyegate (EYEG) is Selling Shares


Yesterday, the VP Engineering of Eyegate (EYEG), Michael Manzo, sold shares of EYEG for $4,608.

In addition to Michael Manzo, 4 other EYEG executives reported Sell trades in the last month.

See today’s analyst top recommended stocks >>

Based on Eyegate’s latest earnings report for the quarter ending March 31, the company posted quarterly revenue of $2.69 million and quarterly net profit of $870.8K. In comparison, last year the company earned revenue of $242K and had a GAAP net loss of $2.78 million. Currently, Eyegate has an average volume of 708.7K.

Company insider trades’ information is brought to you by the DailyInsider, a proprietary algorithm that analyzes insider trading activity to detect the most attractive trading opportunities. To subscribe to the DailyInsider visit this page.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

EyeGate Pharmaceuticals, Inc. is a clinical stage specialty pharmaceutical company, which engages in the development and commercialization of products for treating diseases and disorders of the eye. Its pipeline includes EGP-437 and Ocular Bandage Gel. The company was founded in 1998 and is headquartered in Waltham, MA.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts